☆ 4.7 Article

Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction

DIABETES CARE (2022)

Related references

Note: Only part of the references are listed.

Article Cardiac & Cardiovascular Systems

Effects of treatment with SGLT-2 inhibitors on arginine-related cardiovascular and renal biomarkers

Arne Gessner et al.

Summary: SGLT-2 inhibitors have divergent effects on risk markers related to cardiovascular and renal disease in patients with T2D, which may affect risk estimates associated with these markers. The observed effects may indicate new therapeutic approaches in patients treated with SGLT-2 inhibitors.

CARDIOVASCULAR DIABETOLOGY (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Correlation of physical and cognitive impairment in diabetic and hypertensive frail older adults

Pasquale Mone et al.

Summary: This is the first study to show a significant correlation between 5-m gait speed test and MoCA score in frail diabetic and hypertensive older adults. These results highlight the association between cognitive and physical function, providing valuable information for improving the overall health status of these patients.

CARDIOVASCULAR DIABETOLOGY (2022)

Add to Collection

Article Endocrinology & Metabolism

13. Older Adults: Standards of Medical Care in Diabetes-2022

Summary: The American Diabetes Association provides standards of medical care for diabetes, which includes clinical practice recommendations and guidelines for diabetes care. These guidelines are regularly updated by a committee of multidisciplinary experts.

DIABETES CARE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Heart failure with preserved, mid-range, and reduced ejection fraction across health care settings: an observational study

Annemarijn R. de Boer et al.

Summary: This study found significant variations in both the types of HF and the distribution by sex among HF patients aged 65-79 in different healthcare settings. The proportion of female patients decreased from high-risk communities to general practice to cardiology outpatient settings, with HFpEF being the most common type of HF.

ESC HEART FAILURE (2022)

Add to Collection

Article Medicine, General & Internal

Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease A Meta-analysis

Mukul Bhattarai et al.

Summary: This meta-analysis supports the effectiveness of SGLT2 inhibitors in improving cardiovascular morbidity and mortality in selected patients. However, SGLT2 inhibitors were not associated with a reduced risk of acute myocardial infarction. Future long-term prospective studies are needed to further understand the long-term cardiovascular benefits.

JAMA NETWORK OPEN (2022)

Add to Collection

Review Medicine, Research & Experimental

Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies

Kazunori Omote et al.

Summary: The prevalence of heart failure with preserved ejection fraction (HFpEF) is increasing rapidly, and it has significant impact on the functional capacity and quality of life of patients. Unlike heart failure with reduced ejection fraction, there are limited effective treatments available for HFpEF. Therefore, improved understanding of its pathophysiologic mechanisms and individualized treatment strategies is crucial.

ANNUAL REVIEW OF MEDICINE (2022)

Add to Collection

Article Geriatrics & Gerontology

Cognitive dysfunction correlates with physical impairment in frail patients with acute myocardial infarction

Pasquale Mone et al.

Summary: In frail patients with ST-elevation myocardial infarction, there is a significant correlation between gait speed and cognitive function, which was confirmed in a linear multivariate analysis. Therefore, evaluation of both cognitive and physical conditions should be included in the comprehensive geriatric assessment of hospitalized older STEMI patients.

AGING CLINICAL AND EXPERIMENTAL RESEARCH (2022)

Add to Collection

Article Endocrinology & Metabolism

Heart failure in diabetes

Stanislovas S. Jankauskas et al.

Summary: Heart failure and cardiovascular disorders are the leading cause of death in diabetic patients. This article reviews the main mechanisms underlying the development of diabetic cardiomyopathy and the contributions of different cells in diabetes-related heart failure. It also explores the preclinical tools for studying the disease mechanisms and provides updates on clinical management in the literature.

METABOLISM-CLINICAL AND EXPERIMENTAL (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Neuroprotective Effect of SGLT2 Inhibitors

Agnieszka Pawlos et al.

Summary: SGLT2 inhibitors have neuroprotective potential and can protect against cardiovascular diseases and cognitive impairment in patients with type 2 diabetes mellitus by exerting anti-inflammatory, anti-atherosclerotic effects, improving endothelial function, alleviating oxidative stress, etc.

MOLECULES (2021)

Add to Collection

Editorial Material Endocrinology & Metabolism

Cardiovascular Endocrinology: Evolving Concepts and Updated Epidemiology of Relevant Diseases

Fahimeh Varzideh et al.

FRONTIERS IN ENDOCRINOLOGY (2021)

Add to Collection

Review Endocrinology & Metabolism

Patients With Type 2 Diabetes Mellitus and Heart Failure Benefit More From Sodium-Glucose Cotransporter 2 Inhibitor: A Systematic Review and Meta-Analysis

Chengcong Chen et al.

Summary: The long-term use of SGLT-2 inhibitors can help reduce the risk of mortality and hospitalization for heart failure in patients with type 2 diabetes mellitus and heart failure.

FRONTIERS IN ENDOCRINOLOGY (2021)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

SGLT2 inhibitors in cardiovascular medicine

Fahimeh Varzideh et al.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin

Atsushi Tanaka et al.

Summary: The most recent treatment guidelines for type 2 diabetes recommend the preferential use of SGLT2 inhibitors in patients with high cardiovascular risk or existing cardiovascular disease. This study analyzed data from the EMBLEM trial to investigate the impact of empagliflozin on clinical parameters in patients with both T2D and CVD, based on their use of metformin therapy. The results showed that empagliflozin treatment for 24 weeks improved glycemic control regardless of baseline metformin use, with greater reductions in BMI and hs-TnI seen in patients who received metformin therapy.

CARDIOVASCULAR DIABETOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker et al.

Summary: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Cell Biology

Cognitive Impairment in Frail Hypertensive Elderly Patients: Role of Hyperglycemia

Pasquale Mone et al.

Summary: The study demonstrates the detrimental effects of hypertension and hyperglycemia on endothelial cell function and cognitive decline in older adults. Metformin shows beneficial effects on brain microvascular endothelial cells, improving cell death and reactive oxygen species generation induced by high glucose, and mitigating cognitive impairment.

CELLS (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

Sodium-glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review

Roy Rasalam et al.

Summary: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) significantly reduce the relative risk of hospitalization for heart failure (HHF) regardless of type-2 diabetes mellitus (T2DM) status, and may contribute to efficacy by reversing adverse left ventricular remodeling. Limited available evidence from randomized controlled trials suggests various possible cardioprotective mechanisms of SGLT2is in heart failure.

ESC HEART FAILURE (2021)

Add to Collection

Review Cell Biology

The degree of frailty as a translational measure of health in aging

Susan E. E. Howlett et al.

Summary: Frailty is a state related to age, influenced by multiple factors, and increasing the risk for adverse health outcomes. Age-related damage and decline in repair result in cellular and molecular deficits that scale up to tissue, organ, and system levels, where they are jointly expressed as frailty.

NATURE AGING (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Combinations of cardiac and non-cardiac predictors for prognoses in patients with acute heart failure

Daihiko Hakuno et al.

Summary: This study analyzed the prognostic factors in acute HF patients and found that multi-frailty and PH or mild pancytopenia can synergistically predict HF readmission in HFpEF patients.

EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES (2021)

Add to Collection

Article Clinical Neurology

Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes

Carmen Hierro-Bujalance et al.

ALZHEIMERS RESEARCH & THERAPY (2020)

Add to Collection

Article Endocrinology & Metabolism

Cost-effectiveness of Interventions to Manage Diabetes: Has the Evidence Changed Since 2008?

Karen R. Siegel et al.

DIABETES CARE (2020)

Add to Collection

Review Cardiac & Cardiovascular Systems

SGLT2i: beyond the glucose-lowering effect

Lihua Ni et al.

CARDIOVASCULAR DIABETOLOGY (2020)

Add to Collection

Letter Cardiac & Cardiovascular Systems

Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality Insights From the EMPA-REG OUTCOME Trial

Gianluigi Savarese et al.

CIRCULATION (2019)

Add to Collection

Article Endocrinology & Metabolism

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial

Helena W. Rodbard et al.

DIABETES CARE (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Physical Function, Frailty, Cognition, Depression, and Quality of Life in Hospitalized Adults >= 60 Years With Acute Decompensated Heart Failure With Preserved Versus Reduced Ejection Fraction

Haider J. Warraich et al.

CIRCULATION-HEART FAILURE (2018)

Add to Collection

Article Biochemistry & Molecular Biology

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats

Sebastian Steven et al.

REDOX BIOLOGY (2017)

Add to Collection

Review Endocrinology & Metabolism

Metformin-associated lactic acidosis: Current perspectives on causes and risk

Ralph DeFronzo et al.

METABOLISM-CLINICAL AND EXPERIMENTAL (2016)

Add to Collection

Article Medicine, General & Internal

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Endocrinology & Metabolism

Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease

Jie Hong et al.

DIABETES CARE (2013)

Add to Collection

Review Endocrinology & Metabolism

SGLT inhibitors in management of diabetes

Abd A. Tahrani et al.

LANCET DIABETES & ENDOCRINOLOGY (2013)

Add to Collection

Article Geriatrics & Gerontology

Frailty in older adults: Evidence for a phenotype

LP Fried et al.

JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.